## Sara J Israels

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3281079/publications.pdf

Version: 2024-02-01

45317 66343 8,293 123 42 90 citations h-index g-index papers 127 127 127 8862 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women. Biomedicine and Pharmacotherapy, 2022, 148, 112684.	5.6	2
2	Precursor B-Cell Acute Lymphoblastic Leukemia With MYC and BCL2 Rearrangements Presenting as Extensive Extranodal Disease in an Adolescent. Journal of Pediatric Hematology/Oncology, 2021, 43, e501-e504.	0.6	0
3	Patterns of joint damage in severe haemophilia A treated with prophylaxis. Haemophilia, 2021, 27, 666-673.	2.1	1
4	Acute Myeloid Leukemia Presenting as a Posterior Fossa Tumor. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, 277-278.	0.6	1
5	Magnetic resonance imaging in boys with severe hemophilia A: Serial and endâ€ofâ€study findings from the Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12565.	2.3	4
6	IL-4 Mediated Upregulation of AMPK/SIRT1/PGC-1α Signalling Pathway Is Bypassed By Mitochondrial Complex I Downregulation By NAMPT Inhibition in Venetoclax and Ibrutinib Treated CLL Cells. Blood, 2021, 138, 2616-2616.	1.4	0
7	Epidural Spinal Mass as the Presenting Feature of B-Acute Lymphoblastic Leukemia in a Young Child. Journal of Pediatric Hematology/Oncology, 2020, 42, e845-e847.	0.6	1
8	Association of Mindfulness-Based Interventions With Anxiety Severity in Adults With Cancer. JAMA Network Open, 2020, 3, e2012598.	5.9	54
9	Clinical characterization and hematopoietic stem cell transplant outcomes for congenital sideroblastic anemia caused by a novel pathogenic variant in <i>SLC25A38</i> . Pediatric Blood and Cancer, 2020, 67, e28623.	1.5	5
10	Hemophilia prophylaxis adherence and bleeding using a tailored, frequencyâ€escalated approach: The Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 318-325.	2.3	16
11	A Novel VWD Variant Identified in a Multi-Generational Canadian Ojibway Kindred with a Type 2B VWD Phenotypic Expression. Blood, 2020, 136, 12-13.	1.4	О
12	Pharmacogenomics of Vincristineâ€Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. Clinical Pharmacology and Therapeutics, 2019, 105, 402-410.	4.7	56
13	Platelet Function in the Newborn. , 2019, , 443-457.		3
14	Impact of Vertebral Fractures and Glucocorticoid Exposure on Height Deficits in Children During Treatment of Leukemia. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 213-222.	3.6	11
15	Comparison of light transmission aggregometry and multiple electrode aggregometry for the evaluation of patients with mucocutaneous bleeding. International Journal of Laboratory Hematology, 2019, 41, 133-140.	1.3	22
16	Aberrant splicing contributes to severe α-spectrin–linked congenital hemolytic anemia. Journal of Clinical Investigation, 2019, 129, 2878-2887.	8.2	24
17	Discordant von Willebrand factor (VWF) activity in patients with <i><scp>VWF</scp></i> p.Gly1324Ser confirmed in vitro. Haemophilia, 2018, 24, e57-e59.	2.1	1
18	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI Insight, 2018, 3, .	5.0	71

#	Article	IF	CITATIONS
19	Analysis of procoagulant phosphatidylserineâ€exposing platelets by imaging flow cytometry. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 736-750.	2.3	16
20	Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study. Journal of Bone and Mineral Research, 2018, 33, 1435-1443.	2.8	79
21	Molecular Basis of Platelet Function. , 2018, , 1870-1884.e2.		1
22	Laboratory diagnosis of inherited platelet function disorders. Transfusion and Apheresis Science, 2018, 57, 485-493.	1.0	16
23	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematology,the, 2018, 5, e252-e260.	4.6	31
24	Abstract 3515: Down the rabbit hole with structural effects of FK866 in primary CLL B cells. , 2018, , .		0
25	Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model. Thrombosis Research, 2016, 144, 27-31.	1.7	21
26	Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia. Autophagy, 2016, 12, 1029-1046.	9.1	86
27	Acquired Hemophilia: A Ten Year Population-Based Review of Incidence Rate, Patient Demographics, and Treatment Outcomes in Manitoba, Canada. Blood, 2016, 128, 3783-3783.	1.4	1
28	Geographical variation in the incidence of childhood leukaemia in Manitoba. Journal of Paediatrics and Child Health, 2015, 51, 1121-1126.	0.8	5
29	Experience with central venous access devices ( <scp>CVAD</scp> s) in the Canadian hemophilia primary prophylaxis study ( <scp>CHPS</scp> ). Haemophilia, 2015, 21, 469-476.	2.1	13
30	Increased requirement for central venous catheter replacement in paediatric oncology patients with deep venous thrombosis: A multicentre study. Thrombosis and Haemostasis, 2015, 113, 434-435.	3.4	15
31	Laboratory testing for platelet function disorders. International Journal of Laboratory Hematology, 2015, 37, 18-24.	1.3	35
32	Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3408-3417.	3.6	93
33	Markers of Platelet Activation Are Increased in Adolescents With Type 2 Diabetes. Diabetes Care, 2014, 37, 2400-2403.	8.6	12
34	von Willebrand disease and platelet disorders. Haemophilia, 2014, 20, 59-64.	2.1	25
35	Intracranial Atypical Teratoid/Rhabdoid Tumor Presenting as an Axillary Mass: A Case Report and Review of Literature. Pediatric and Developmental Pathology, 2014, 17, 122-125.	1.0	4
36	Cancer incidence, morbidity, and survival in Canadian first nation children: A Manitoba populationâ€based study from the cancer in young people in Canada (CYPâ€C) registry. Pediatric Blood and Cancer, 2014, 61, 2164-2169.	1.5	7

#	Article	IF	Citations
37	The development of bone mineral lateralization in the arms. Osteoporosis International, 2013, 24, 999-1006.	3.1	2
38	What we have learned from inherited platelet disorders. Pediatric Blood and Cancer, 2013, 60, S2-7.	1.5	14
39	Platelet Function in the Newborn. , 2013, , 503-516.		4
40	Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. Journal of Thrombosis and Haemostasis, 2013, 11, 460-466.	3.8	43
41	A Dutch Fanconi Anemia <i>FANCC &lt; /i&gt;Founder Mutation in Canadian Manitoba Mennonites. Anemia, 2012, 2012, 1-6.</i>	1.7	15
42	High Incidence of Vertebral Fractures in Children With Acute Lymphoblastic Leukemia 12 Months After the Initiation of Therapy. Journal of Clinical Oncology, 2012, 30, 2760-2767.	1.6	120
43	Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. Journal of Thrombosis and Haemostasis, 2012, 10, 2494-2502.	3.8	76
44	Unintended benefit of anabolic steroid use in hemophilia B leiden. American Journal of Hematology, 2012, 87, 122-123.	4.1	4
45	Central Venous Catheters and Venous Thrombotic Events in Pediatric Oncology Patients: A Multicenter Case Control Study. Blood, 2012, 120, 3400-3400.	1.4	0
46	Refinement of the hereditary xerocytosis locus on chromosome 16q in a large Canadian kindred. Blood Cells, Molecules, and Diseases, 2011, 47, 226-231.	1.4	20
47	Platelet disorders in children: A diagnostic approach. Pediatric Blood and Cancer, 2011, 56, 975-983.	1.5	63
48	Inherited disorders of platelet function and challenges to diagnosis of mucocutaneous bleeding. Haemophilia, 2010, 16, 152-159.	2.1	34
49	Development of North American Consensus Guidelines for Medical Laboratories That Perform and Interpret Platelet Function Testing Using Light Transmission Aggregometry. American Journal of Clinical Pathology, 2010, 134, 955-963.	0.7	173
50	Mechanisms of oral bacteria-induced platelet activation. Canadian Journal of Physiology and Pharmacology, 2010, 88, 510-524.	1.4	29
51	Palmitoylation supports the association of tetraspanin CD63 with CD9 and integrin $\hat{l}$ ±llb $\hat{l}$ 23 in activated platelets. Thrombosis Research, 2010, 125, 152-158.	1.7	33
52	Phenotypic Evaluation of a Family Cohort with Hemolytic Anemia. Blood, 2010, 116, 3214-3214.	1.4	0
53	Results of an External Proficiency Testing Exercise on Platelet Dense-Granule Deficiency Testing by Whole Mount Electron Microscopy. American Journal of Clinical Pathology, 2009, 131, 671-675.	0.7	50
54	Diagnostic Evaluation of Platelet Function Disorders in Neonates and Children: An Update. Seminars in Thrombosis and Hemostasis, 2009, 35, 181-188.	2.7	51

#	Article	IF	CITATIONS
55	Advanced Vertebral Fracture Among Newly Diagnosed Children With Acute Lymphoblastic Leukemia: Results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Research Program. Journal of Bone and Mineral Research, 2009, 24, 1326-1334.	2.8	188
56	Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death and Differentiation, 2008, 15, 171-182.	11.2	600
57	Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection. Cardiovascular & Hematological Disorders Drug Targets, 2008, 8, 99-117.	0.7	126
58	Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy, 2008, 4, 195-204.	9.1	321
59	Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. Journal of Cell Science, 2007, 120, 4155-4166.	2.0	394
60	Platelet tetraspanin complexes and their association with lipid rafts. Thrombosis and Haemostasis, 2007, 98, 1081-1087.	3.4	33
61	Platelet Function in the Newborn. , 2007, , 431-442.		2
62	A role for von Willebrand factor in Streptococcus sanguis-induced platelet activation. Thrombosis and Haemostasis, 2007, 98, 1382-1384.	3.4	6
63	10 Year Musculoskeletal Outcomes with Tailored Primary Prophylaxis: The Canadian Hemophilia Prophylaxis Study Blood, 2007, 110, 84-84.	1.4	3
64	Platelet tetraspanin complexes and their association with lipid rafts. Thrombosis and Haemostasis, 2007, 98, 1081-7.	3.4	14
65	A role for von Willebrand factor in Streptococcus sanguis-induced platelet activation. Thrombosis and Haemostasis, 2007, 98, 1382-4.	3.4	3
66	Antiplatelet therapy in children. Thrombosis Research, 2006, 118, 75-83.	1.7	43
67	Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. Journal of Thrombosis and Haemostasis, 2006, 4, 1228-1236.	3.8	224
68	Platelet Tetraspanin Complexes and Their Relation to Lipid Rafts Blood, 2006, 108, 1530-1530.	1.4	0
69	Bleeding disorders: characterization, dental considerations and management. Journal of the Canadian Dental Association, 2006, 72, 827.	0.6	42
70	Gynaecological and Obstetric Management of Women With Inherited Bleeding Disorders. Journal of Obstetrics and Gynaecology Canada, 2005, 27, 707-718.	0.7	45
71	CD63 modulates spreading and tyrosine phosphorylation of platelets on immobilized fibrinogen. Thrombosis and Haemostasis, 2005, 93, 311-318.	3.4	58
72	A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia, 2004, 10, 679-683.	2.1	29

#	Article	IF	CITATIONS
73	Home management of haemophilia. Haemophilia, 2004, 10, 118-133.	2.1	100
74	CD63 Modulates Spreading and Tyrosine Phosphorylation of Platelets on Immobilized Fibrinogen Blood, 2004, 104, 1567-1567.	1.4	3
75	Retrospective Analysis of the Minimum Dosage Requirements for Enoxaparin in Neonates with Thromboembolic Disease Blood, 2004, 104, 1770-1770.	1.4	2
76	Are There Potential Predictors for Response to Enoxaparin in the Neonatal Population? Blood, 2004, 104, 4083-4083.	1.4	0
77	In-Vitro Stability of B-Domain Deleted Recombinant Factor VIII in Syringe-Based Continuous Infusion Devices Blood, 2004, 104, 3969-3969.	1.4	0
78	Coagulation Abnormalities in Patients with Noonan Syndrome - a Single Centre Case Series Blood, 2004, 104, 1035-1035.	1.4	0
79	Clinical Associations and Significance of Biphasic aPTT Transmittance Waveforms Blood, 2004, 104, 3964-3964.	1.4	O
80	BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene, 2003, 22, 4734-4744.	5.9	199
81	Neonatal Platelet Function. Seminars in Thrombosis and Hemostasis, 2003, 29, 363-372.	2.7	105
82	Platelets and Anti-platelet Therapy. Journal of Pharmacological Sciences, 2003, 93, 381-396.	2.5	88
83	In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood, 2002, 99, 1364-1372.	1.4	348
84	Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyzer. Journal of Pediatrics, 2001, 138, 116-119.	1.8	103
85	Incorporation of MAP Kinases Into the Platelet Cytoskeleton. Thrombosis Research, 2001, 103, 25-34.	1.7	15
86	CD63 Associates with the $\hat{l}\pm IIb\hat{l}^23$ Integrin-CD9 Complex on the Surface of Activated Platelets. Thrombosis and Haemostasis, 2001, 85, 134-141.	3.4	60
87	BNIP3 and Genetic Control of Necrosis-Like Cell Death through the Mitochondrial Permeability Transition Pore. Molecular and Cellular Biology, 2000, 20, 5454-5468.	2.3	585
88	Thrombopoietin and Neonatal Thrombocytopenia: Commentary on the article by Sola et al. on page 208. Pediatric Research, 2000, 47, 176-176.	2.3	3
89	Outcome of Pediatric Thromboembolic Disease: A Report from the Canadian Childhood Thrombophilia Registry. Pediatric Research, 2000, 47, 763-766.	2.3	459
90	Apoptosis in heart failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8144-8149.	7.1	553

#	Article	IF	Citations
91	The ribonucleotide reductase R2 gene is a non-transcribed target of c-Myc-induced genomic instability. Gene, 1999, 238, 351-365.	2.2	29
92	Platelet Dense Granules. Thrombosis Research, 1999, 95, 1-18.	1.7	250
93	α1-Antitrypsin Deficiency With Fatal Intracranial Hemorrhage in a Newborn. Journal of Pediatric Hematology/Oncology, 1999, 21, 447-450.	0.6	8
94	Impaired Signal Transduction in Neonatal Platelets. Pediatric Research, 1999, 45, 687-691.	2.3	51
95	Effects of the Mitogen-Activated Protein (MAP) Kinase Kinase Inhibitor 2-(2′-Amino-3′-methoxyphenyl)-oxanaphthalen-4-one (PD98059) on Human Platelet Activation. Biochemical Pharmacology, 1998, 55, 1759-1767.	4.4	19
96	Familial Neuroblastoma. Journal of Pediatric Hematology/Oncology, 1998, 20, 489-493.	0.6	5
97	Granzyme B (GraB) Autonomously Crosses the Cell Membrane and Perforin Initiates Apoptosis and GraB Nuclear Localization. Journal of Experimental Medicine, 1997, 185, 855-866.	8.5	216
98	Identification of Patients with Storage Pool Deficiency Using ATP Release and Dense Granule Counts. Hematology, 1997, 2, 161-167.	1.5	6
99	Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6939-6942.	7.1	386
100	Acquired inhibitors to factors V and X after exposure to topical thrombin: Interference with monitoring of low molecular weight heparin and warfarin. Journal of Pediatrics, 1997, 131, 480-483.	1.8	20
101	In-vitro stability of porcine factor VIII (Hyate:CR). Haemophilia, 1997, 3, 21-23.	2.1	7
102	Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors. , 1997, $56$ , $112-118$ .		18
103	Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors. American Journal of Hematology, 1997, 56, 112-118.	4.1	4
104	Mycobacterium fortuitum interstitial pneumonia with vasculitis in a child with Wilms' tumor. Pediatric Infectious Disease Journal, 1997, 16, 996-1000.	2.0	9
105	Deficient Thromboxane Synthesis and Response in Platelets from Premature Infants. Pediatric Research, 1997, 41, 218-223.	2.3	74
106	Deposition of Transforming Growth Factor- $\langle i \rangle \hat{l}^2 \langle  i \rangle$ in the Marrow in Myelofibrosis, and the Intracellular Localization and Secretion of TGF- $\langle i \rangle \hat{l}^2 \langle  i \rangle$ by Leukemic Cells. American Journal of Clinical Pathology, 1995, 103, 574-582.	0.7	34
107	The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion, 1995, 35, 548-551.	1.6	47
108	The empty sack syndrome: a platelet storage pool deficiency associated with empty dense granules. British Journal of Haematology, 1994, 86, 574-582.	2.5	28

#	Article	IF	Citations
109	Primary hypothyroidism with intracranial hypertension and pituitary hyperplasia. Pediatric Neurology, 1994, 10, 166-168.	2.1	21
110	Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet, The, 1994, 344, 703-707.	13.7	315
111	Development of Antibodies to Bovine and Human Factor V in Two Children After Exposure to Topical Bovine Thrombin. Journal of Pediatric Hematology/Oncology, 1994, 16, 249-254.	0.6	48
112	Evaluation of families wherein a single male manifests a phenotype of X-linked lymphoproliferative disease (XLP). American Journal of Medical Genetics Part A, 1993, 47, 458-463.	2.4	6
113	Role of transforming growth factor- $\hat{l}^2$ in chronic lymphocytic leukemia. Leukemia Research, 1993, 17, 81-87.	0.8	12
114	A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. Journal of Pediatrics, 1992, 120, 522-527.	1.8	76
115	Inherited platelet-storage pool deficiency associated with a high incidence of acute myeloid leukaemia. British Journal of Haematology, 1991, 79, 246-255.	2.5	56
116	Deficient Collagen-Induced Activation in the Newborn Platelet. Pediatric Research, 1990, 27, 337-343.	2.3	86
117	Studies in patients with bleeding disorders show that platelet-vessel interaction is important for thromboxane formation in bleeding time wounds. Thrombosis Research, 1990, 60, 79-85.	1.7	5
118	Early coagulopathy in severe iron poisoning. Journal of Pediatrics, 1988, 113, 695-697.	1.8	17
119	Contractile Activity of Neonatal Platelets. Pediatric Research, 1987, 21, 293-295.	2.3	21
120	Childhood stroke associated with protein C or S deficiency. Journal of Pediatrics, 1987, 111, 562-564.	1.8	118
121	Differential effects of spermine on aggregation, inositol phosphate formation and protein phosphorylation in human platelets in response to thrombin, arachidonic acid and lysophosphatidic acid. Biochimica Et Biophysica Acta - General Subjects, 1986, 883, 247-252.	2.4	15
122	Activation of permeabilized platelets by inositol-1, 4, 5-trisphosphate. Thrombosis Research, 1985, 40, 499-509.	1.7	35
123	Synovial sarcoma in childhood. American Journal of Roentgenology, 1984, 142, 803-806.	2.2	33